Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1508355

Identification and validation of monocyte to macrophage differentiation associated (MMD) as a prognostic biomarker in gastric cancer

Provisionally accepted
  • 1 First Hospital of Lanzhou University, Lanzhou, China
  • 2 Storr Liver Centre, Westmead Institute for Medical Research, Westmead, Australia

The final, formatted version of the article will be published soon.

    Background: Gastric cancer (GC) has a very poor prognosis as most cases are diagnosed at a late stage, which can be partially attributed to a lack of reliable diagnostic biomarkers. Our study reveals a close correlation between monocyte to macrophage differentiation associated (MMD) and GC. Methods: We analyzed data from The Cancer Genome Atlas (TCGA). A close association between MMD levels and the clinicopathological features of gastric cancer patients was identified using Cox regression analysis and KM plot database analysis. Bioinformatics data were validated by real-time polymerase chain reaction and western blot analysis in GC cells. The impact of MMD on GC was examined using multiple complementary assays, including colony formation assay, CCK-8 assay, cell cycle analysis, apoptosis assessment, wound healing assay, transwell assay, and subcutaneous xenograft tumor formation assay in mice. Results: High levels of MMD were observed in GC tissues. MMD accelerated cell growth and metastasis, and suppressed apoptosis in GC cells. MMD inhibition significantly suppressed the growth of xenograft tumors in mice. Further studies had revealed that MMD expression was suppressed by miR-200b-3p in GC. Dual luciferase experiment indicated that MMD is a direct target gene of miR-200b-3p. MMD might play an oncogenic role in GC by acting as a direct target of miR-200b-3p. Conclusion: MMD plays an oncogenic role in gastric cancer. It may serve as a potential biomarker for GC diagnosis and a therapeutic target.

    Keywords: MMD, Stomach Neoplasms, prognosis, biomarker, miR-200b-3p

    Received: 09 Oct 2024; Accepted: 27 Mar 2025.

    Copyright: © 2025 Bai, Chen, Ji, Wang, Zhou, Guo and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yongning Zhou, First Hospital of Lanzhou University, Lanzhou, China
    Qinghong Guo, First Hospital of Lanzhou University, Lanzhou, China
    Liang Qiao, Storr Liver Centre, Westmead Institute for Medical Research, Westmead, NSW 2145, Australia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more